The outcomes of patients with relapsed or refractory (R-R) acute lymphoblastic leukemia (ALL) are poor. Inotuzumab ozogamicin and blinatumomab have single-agent activity in R-R ALL. Their addition to low-intensity chemotherapy may further improve the outcomes of patients with ALL in their first relapse. METHODS: The chemotherapy was lower in intensity than conventional hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone and was called mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone (or mini-HCVD). Inotuzumab was given on day 3 of each of the first 4 cycles at 1.8 to 1.3 mg/m 2 for cycle 1, and this was followed by 1.3 to 1.0 mg/m 2 for subsequent cycles. From patient 39 onward, the inotuzumab dose was reduced and fractionated into weekly doses (0.6 and 0.3 mg/m 2 during cycle 1 and 0.3 and 0.3 mg/m 2 during subsequent cycles), and blinatumomab was administered for up to 4 cycles after inotuzumab therapy. RESULTS: Forty-eight patients with Philadelphia chromosome-negative ALL with a median age of 39 years were treated during their first relapse. Overall, 44 patients (92%) responded, with 35 of them (73%) achieving a complete response. The overall minimal residual disease negativity rate among the responders was 93%. Twenty-four patients (50%) underwent allogeneic stem cell transplantation (ASCT). Veno-occlusive disease of any grade occurred in 5 patients (10%). With a median follow-up of 31 months, the median progression-free survival (PFS) and the median overall survival (OS) were 11 and 25 months, respectively. The 2-year PFS and OS rates were 42% and 54%, respectively. Of the 24 patients (50%) who underwent ASCT, 14 patients were alive at the last follow-up (13 [54%] in remission). Of the remaining 20 responding patients who did not undergo subsequent ASCT, 6 (30%) remained in remission at the last follow-up. According to propensity score matching, the combination of mini-HCVD and inotuzumab with or without blinatumomab conferred better outcomes than intensive salvage chemotherapy or inotuzumab alone. CONCLUSIONS: The combination of inotuzumab and low-intensity mini-HCVD chemotherapy with or without blinatumomab shows encouraging results in patients with ALL in first salvage. Cancer 2018;124:4044-4055.
INTRODUCTION
Significant progress has been accomplished in acute lymphoblastic leukemia (ALL). With modern intensive combination chemotherapy, the complete response (CR) rate in adults with ALL is 80% to 90%, but the cure rate is 40% to 50%. 1, 2 The outcomes of patients who experience relapse are poor. Few patients can be bridged to allogeneic stem cell transplantation (ASCT), the ultimate treatment with durable remissions. [2] [3] [4] Salvage cytotoxic chemotherapy results in modest CR rates of 30% to 40% in first salvage, and the outcome is poor with a median survival of 6 months and a 5-year survival rate of less than 7%.
Cancer October 15, 2018 Modern innovative approaches, including new antibody therapies such as inotuzumab ozogamicin, 5 the bispecific antibody construct blinatumomab, 6 and chimeric antigen receptor (CAR) T-cell therapies, 7, 8 have recently shown promise for patients with relapsed or refractory (R-R) ALL, improving outcomes in comparison with conventional chemotherapy.
Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, resulted in an overall response rate of 80% and a median survival of 7.7 months among patients with R-R ALL. 5 Blinatumomab, a bispecific T-cell-engaging CD3-CD19 antibody construct, resulted in an overall response rate of 44% and a median survival of 7.7 months in a similar R-R ALL population. 6 Better results were obtained in patients treated earlier (salvage 1 vs salvage 2 or later) and in patients with a minimal disease burden; such patients can experience long-term survival. [8] [9] [10] [11] The addition of inotuzumab ozogamicin as targeted immunotherapy to effective low-intensity chemotherapy in patients with R-R ALL has shown promising results with an overall response rate of 80% and a median survival of 11 months versus 6 months with single-agent inotuzumab ozogamicin in similar patient populations. 10 Such a strategy may translate into a significant long-term survival benefit when it is used for patients in first salvage. Herein, we report the results of an ongoing phase 2 study that is evaluating the efficacy and safety of this combination in patients with ALL in first salvage.
MATERIALS AND METHODS

Study Design and Participants
Patients with Philadelphia chromosome-negative, CD22-positive ALL in first salvage were eligible. Patients had to have an Eastern Cooperative Oncology Group performance status of 3 or less, normal cardiac function (defined by an ejection fraction > 50%), and adequate organ function (serum bilirubin ≤ 1.5 mg/dL and serum creatinine ≤ 2.0 mg/dL). Patients were excluded if they had an active infection not controlled by antibiotics, clinical evidence of grade 3/4 heart failure as defined by the New York Heart Association criteria, or a second malignancy. All patients signed an informed consent form in accordance with the Declaration of Helsinki, and the study was approved by the institutional review board of The University of Texas MD Anderson Cancer Center. The trial was registered at ClinicalTrials.gov with the identifier NCT01371630.
Treatment
The chemotherapy was lower in intensity than conventional hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone and was called minihyperfractionated cyclophosphamide, vincristine, and dexamethasone (or mini-HCVD). 10, 12 Briefly, odd cycles included cyclophosphamide (150 mg/m 2 every 12 hours on days 1-3) and dexamethasone (20 mg/d on days 1-4 and 11-14) given at a 50% dose reduction; no anthracycline was administered. Vincristine (2-mg flat dose) was given on days 1 and 8. Even cycles included methotrexate at 250 mg/m 2 on day 1 (a 75% dose reduction) and cytarabine at 0.5 g/m 2 every 12 hours on days 2 and 3 (an 83% dose reduction). Inotuzumab was administered on day 3 of each of the first 4 cycles. Inotuzumab was given at 1.8 to 1.3 mg/m 2 in cycle 1, and this was followed by 1.3 to 1.0 mg/m 2 for subsequent cycles. Cycles were administered every 4 weeks for a total of 8 cycles.
Rituximab was administered on days 1 and 11 of cycles 1 and 3 and on days 1 and 8 of cycles 2 and 4 in patients with CD20 expression ≥ 20%. 13 Central nervous system prophylaxis consisted of intrathecal therapy with methotrexate and cytarabine given alternately on days 2 and 7 of each cycle for a total of 8 doses. The order of intrathecal chemotherapy was reversed with the even cycles-cytarabine on day 2 and methotrexate on day 7-to avoid simultaneous systemic and intrathecal methotrexate, which was previously suspected to cause rare demyelination and neurotoxicity. For patients presenting with active central nervous system disease that was confirmed by a cytologic examination of the cerebrospinal fluid (CSF), the intrathecal regimen was repeated twice weekly until the CSF became clear of leukemic cells and the CSF cell count normalized. Patients then received intrathecal therapy once a week for 4 weeks or until the initiation of the next cycle of chemotherapy when the regimen was resumed.
Maintenance therapy was given for 3 years with monthly vincristine at 2 mg for 1 year, with prednisone at 50 mg daily for 5 days every month for 1 year, with 6-mercaptopurine at 50 mg twice daily for 3 years, and with oral methotrexate at 10 mg/m 2 weekly for 3 years (the 6-mercaptoprine, Oncovin (vincristine), methotrexate, and prednisone [POMP] regimen). The initiation of maintenance due to treatment-related toxicity before completion of the consolidation phase was allowed. Dose reductions of the cytotoxic agents according to the types and degrees of side effects or toxicity were permitted and followed previously published guidelines. [13] [14] [15] The decision to proceed with ASCT was at the discretion of the treating physician after discussion with the patient. The factors taken into account were usually the salvage status (salvage 1 vs salvage 2), the achievement of a negative minimal residual disease (MRD) status, and the lack of prior Cancer October 15, 2018 ASCT performed during the first CR (a lower risk of veno-occlusive disease [VOD] ).
To reduce the risk of VOD and further improve the outcome, the protocol was amended in February 2017 to use lower doses of weekly inotuzumab and to add to the consolidation phase 4 cycles of blinatumomab. This amendment was in effect from salvage patient 39 onward. The weekly lower dose schedule of inotuzumab was found to be safe and as effective as the single monthly schedule. Favorable outcomes correlated with the lower clearance rate and better area under the curve provided by the weekly lower dose schedule in comparison with the higher loading doses obtained with the single monthly schedule. 16 After this amendment, inotuzumab (2 weekly fractioned doses) was given for a total of 0.9 mg/m 2 during cycle 1 (fractionated into 0.6 mg/m 2 on day 2 and 0.3 mg/ m 2 on day 8 of cycle 1) and for a total of 0.6 mg/m 2 during cycles 2, 3, and 4 (fractionated into 0.3 mg/m 2 on day 2 and 0.3 mg/m 2 on day 8 of the subsequent 3 cycles). Only 4 cycles of hyper-CVD plus inotuzumab were given (ie, cycles 1-4). Blinatumomab was administered after the inotuzumab-based cycles for a total of 4 cycles and before the initiation of the maintenance therapy (ie, cycles 5-8). Blinatumomab was administered by continuous infusion at a standard dose of 9 µg/d in the first 4 days of the first cycle; then, the dose was escalated to 28 µg/d for the rest of the cycle and to 28 µg/d for 4 weeks in the subsequent cycles. Cycles were 6 weeks with 4 weeks on and 2 weeks off.
Supportive Care
Supportive care measures were implemented according to standard guidelines. Tumor lysis prophylaxis with allopurinol or alternatives such as rasburicase and appropriate intravenous hydration were administered in the first course to all patients. Prophylactic antimicrobial therapy was administered to all patients during periods of neutropenia beginning in induction. Pegfilgrastim (6 mg) was subcutaneously administered on day 4/5 (+2 days) of each of the induction/consolidation cycles. Oral ursodiol at 300 mg 3 times daily was systematically administered as VOD prophylaxis from September 2015 onward.
Outcomes
The primary endpoints of the analysis were the overall response rate (including CR, complete response with incomplete platelet recovery [CRp] , and complete response with incomplete hematologic recovery [CRi] ) and the overall survival (OS). Secondary endpoints included safety measures, progression-free survival (PFS), the rate of subsequent ASCT, and the MRD negativity rate of patients who achieved CR or CRp. CR was defined as the presence of ≤5% blasts in the bone marrow with more than 1 × 10 9 /L neutrophils, more than 100 × 10 9 /L platelets in the peripheral blood, and no extramedullary disease. CRp was defined as CR except for a platelet count less than 100 × 10 9 /L. CRi was defined as CR but with an absolute neutrophil count less than 1 × 10 9 /L and a platelet count less than 100 × 10 9 /L. An MRD assessment by 6-color flow cytometry was performed on whole bone marrow specimens as previously described. 17 A distinct cluster of at least 20 cells that showed altered antigen expression was regarded as an aberrant population, and this yielded a sensitivity of 1 in 10,000 cells (for adequate specimens in which 2 × 10 5 cells could be collected). Relapse was defined by the recurrence of more than 5% lymphoblasts in a bone marrow aspirate unrelated to recovery or by the presence of extramedullary disease. PFS was calculated from the time of response until relapse or death. OS was calculated from the time of treatment initiation until death.
Adverse events were defined as any event that occurred between the first dose and 2 months after the last dose, all treatment-related events that occurred after the last dose, and all cases of VOD (of any cause) that occurred within 2 years after inotuzumab therapy. VOD was assessed and diagnosed by the investigators and was evaluated according to previously defined clinical criteria.
Statistical Analysis
This is a phase 2 study of R-R, Philadelphia chromosome-negative ALL in which 79 consecutive patients were treated. This report concerns the 48 patients treated in first salvage. The trial was continuously monitored with an early stopping rule in place if it was ever likely that the trial's OS would be less than that of previous similar trials. No stopping rules were met. Survival curves were plotted with the Kaplan-Meier method and were compared with the log-rank test. Differences in subgroups by different covariates were evaluated with the chi-square test or Fisher's exact test for nominal values and with the Mann-Whitney U test for continuous variables.
For a comparison with a historical cohort of patients treated with inotuzumab ozogamicin and with standard salvage chemotherapy, 1:1 propensity score matching was performed to balance the following covariates in first salvage between cohorts for the evaluation of response and survival: age, sex, performance status, salvage 1 status (primary refractory, CR duration < 12 months, or CR duration ≥ 12 months), prior ASCT, white blood cell count, percentage of blasts in bone marrow aspirates, Cancer October 15, 2018 karyotype, and percentage of CD20 and CD22 by flow cytometry. 18 Multiple imputations were performed before the calculation of propensity scores for missing data to reduce bias. 19 Censoring at the time of ASCT was performed to remove the effect of ASCT on survival for the comparison between propensity score-matched cohorts. Significance was defined as a P value < .05.
RESULTS
Patient Characteristics and Treatment
From November 2012 to January 2018, 48 patients in first salvage were treated. The patients' baseline characteristics are summarized in Table 1 . Their median age was 39 years (range, 18-87 years). Thirty-eight patients (79%) received mini-HCVD and inotuzumab, and 10 patients (21%) received the combination of mini-HCVD and inotuzumab followed by blinatumomab. Five patients (10%) had primary refractory disease, and 23 (48%) had a first CR duration longer than 12 months. Prior ASCT had failed for 7 patients (15%). Thirteen patients (27%) had a diploid karyotype, and 6 (13%) had 11q23 abnormalities; 4 of the latter patients (8%) had t(4;11). The median CD22 expression was 95% (range, 20%-100%). The median CD19 expression was 99.9% (range, 46.5%-100%). Nine patients (19%) were CD20-positive and received rituximab during the first 4 cycles. There was no difference in patients' baseline characteristics between those who received the original treatment and those who received the modified one, including weekly inotuzumab followed by blinatumomab (data not shown). No patients had received prior therapy with inotuzumab or blinatumomab before their enrollment into the study.
Response
Overall, 44 of the 48 patients responded for an overall response rate of 92% (Table 2) . Thirty-five patients (73%) achieved CR, 8 patients (17%) had CRp, and 1 patient (2%) had CRi. Three patients (6%) had resistant disease, and 1 patient (2%) died within 4 weeks of the start of therapy. All patients with primary refractory disease (n = 5) and those with a first CR duration longer than 12 months (n = 23) responded for an overall response rate of 100%. The response rate for patients with a first CR duration shorter than 12 months was 80%. Overall, patients received a median of 3 cycles of therapy (range, 1-8 cycles). Twenty-four patients (50%) underwent ASCT after a median of 3 months with a second CR (range, <1 to 9 months).
Among the patients who responded, 41 patients were assessed for their MRD status at the time of the morphologic response. The MRD negativity rates at the time of the morphologic response and at any time within 3 cycles were 68% and 93%, respectively. The overall complete cytogenetic response rate among the 21 patients with a morphologic response and abnormal cytogenetics available for assessment was 90% (19 of 21 responses).
Survival Outcomes
With a median follow-up of 31 months (range, 1-60 months), 26 patients (54%) were alive, and 23 of these patients (48%) were in CR (13 after ASCT). The estimated 2-year OS rate was 54% (95% confidence interval [CI], 37%-68%), and the PFS rate was 42% (95% CI, 27%-58%). The median OS and PFS were 25 and 11 months, respectively (Fig. 1A) . The 1-year OS rates for patients treated with the original combination (n = 38) and patients treated with the modified one (including a weekly lower dose of inotuzumab followed by blinatumomab; n = 10) were 63% (95% CI, 46%-76%) and not available, respectively. Survival by MRD status is shown in Fig. 1B for the 41 patients assessed for MRD. Patients achieving MRD negativity had better outcomes. The 1-year OS rates were 74% (95% CI, 55%-85%) for patients with an MRD-negative status (n = 38; median OS, 47 months) and 33% (95% CI, 1%-77%) for patients with an MRD-positive status (n = 3; median OS, 5 months; P = .065). Six patients (13%) achieved a durable MRD-negative second remission without subsequent ASCT.
Feasibility of Subsequent ASCT
Among the 48 patients treated, 24 patients (50%) were able to proceed to ASCT in their second CR (5 related donors, 9 matched unrelated donors, and 10 haploidentical donors). At the time of this writing, 13 of these 24 patients remained in remission and alive after ASCT. The 2-year OS rate of patients who underwent ASCT in salvage 1 was 65% (95% CI, 44%-86%) with a median OS of 38 months. The median time from the start of therapy to ASCT was 18 weeks (range, 8-34 weeks). In a landmark analysis at week 15, the 2-year OS rates for patients who underwent subsequent ASCT and those who did not were 64% (95% CI, 44%-86%) and 52% (95% CI, 25%-80%), respectively (P = .8317; Fig. 2 ). The median OS was 38 months and not reached, respectively. The median time from the end of inotuzumab therapy to ASCT was 10 weeks (range, 4-40 weeks). VOD was observed in 3 of 24 patients (13%) who underwent subsequent ASCT and in 2 of 24 patients (8%) who did not; prior ASCT had failed for these 2 patients. VOD was observed in 5 of 38 patients (13%) treated with mini-HCVD and inotuzumab and in 0 of 10 patients (0%) treated with mini-HCVD, inotuzumab, and blinatumomab (4 of the 10 subsequently underwent ASCT). Of the 24 patients who underwent ASCT during their second remission, 10 died (2 because of VOD and 8 because of relapse); 14 patients were alive at the time of this writing (13 achieved CR; 1 was alive after a relapse).
Safety
All 48 patients were evaluable for safety analyses. The treatment was well tolerated, with most side effects being grade 1 to 2. Early mortality, defined as death within 4 weeks, was observed in 1 patient (2%). Overall, patients received a median of 3 cycles of induction-consolidation therapy (range, 1-8 cycles). Of the 142 induction/consolidation cycles received by all the patients, 41% were delivered within 4 weeks, 53% were delivered within 4 to 8 weeks, and 6% were delivered after 8 weeks. Ten patients (21%) received a median of 2 cycles of blinatumomab (range, 1-4 cycles). Of the 5 patients who received later maintenance, 3 switched to maintenance before completing their full induction-consolidation therapy (median number of cycles, 4; range, 4-5) for myelosuppression (n = 1), deconditioning (n = 1), and infections (n = 1). Twelve patients (25%) received all 4 planned cycles of inotuzumab, and 2 (4%) received all 4 planned cycles of blinatumomab. Five patients (10%) had an inotuzumab dose reduction (1 for thrombocytopenia, 2 for liver dysfunction, 1 for sepsis, and 1 for intractable nausea) after a median of 2 cycles (range, 2-4 cycles).
The median times to platelet and neutrophil recovery were 26 and 17 days, respectively, for cycle 1 and 22 and 15 days, respectively, for subsequent cycles. Overall, 79% of the patients had prolonged thrombocytopenia beyond 6 weeks during either induction ( (Table 3) . Cancer October 15, 2018 VOD occurred in 5 patients (10%; median age, 39 years; range, 26-50 years) after a median of 3 cycles (range, 1-5). All 5 patients were exposed to ASCT; 2 underwent ASCT before inotuzumab therapy, and 3 underwent ASCT after inotuzumab therapy.
After the emergence of VOD, the study was amended: the inotuzumab dose was reduced to 0.9 mg/ m 2 during the first cycle and to 0.6 mg/m 2 during subsequent cycles and was fractionated into 2 weekly doses. In addition, blinatumomab was introduced with the aim of distancing ASCT from the last dose of inotuzumab without compromising the efficacy of the regimen. There was a significant decrease in the VOD rates. The rates were 13% (5 of 38) with the original schedule and 0% (0 of 10) after the protocol amendment. Five of the 5 cases of VOD were fatal, with 2 deaths being directly attributed to VOD (Table 4) .
Propensity Score Matching With Historical Cohorts
In a post hoc analysis, we compared the outcomes obtained with mini-HCVD in combination with inotuzumab with or without blinatumomab with our previous experience in similar patients treated with standard salvage chemotherapy (n = 89) or with inotuzumab monotherapy (n = 29). Comparing standard salvage chemotherapy with the combination of mini-HCVD and inotuzumab, propensity score matching identified 37 patients in each cohort (Supporting Table 1 ). The overall response rates for standard chemotherapy and the combination of mini-HCVD and inotuzumab with or without blinatumomab were 68% (95% CI, 52%-83%) and 97% (95% CI, 92%-100%), respectively (P = .010). The median PFS was 5 months (95% CI, 2.4-7.8 months) and 17 months (95% CI, not available), respectively (P < .001; 3A) . The median OS was 9 months (95% CI, 5.3-12.9 months) and not reached (95% CI, not available), respectively (P = .007; Fig. 3B ).
Comparing inotuzumab monotherapy with the combination of mini-HCVD and inotuzumab with or without blinatumomab, propensity score matching identified 24 patients in each cohort (Supporting Table 2 ). The overall response rates for inotuzumab alone and the combination of mini-HCVD and inotuzumab with or without blinatumomab were 79% (95% CI, 62%-97%) and 92% (95% CI, 80%-100%), respectively (P = .018). The median PFS was 9 months (95% CI, 6.3-10.8 months) and 12 months (95% CI, 7.6-16.8 months), respectively (P = .049; Fig. 3C ). The median OS was 9 months (95% CI, 4.1-13.6 months) and 17 months (95% CI, 10.6-22.9 months), respectively (P = .065; Fig. 3D ).
DISCUSSION
In this phase 2 study, the immunochemotherapy combination of inotuzumab and mini-HCVD with or without blinatumomab was safe and effective in patients with ALL in first salvage. The overall response rate was 92%, and the 2-year PFS and OS rates were 42% and 54%, respectively. The results are encouraging and compare favorably with our historical data for salvage 1 with standard chemotherapy (median survival, 4 months) and single-agent inotuzumab (median survival, 9 months) or blinatumomab (median survival, 11 months). 5, 6 This benefit was obtained without increased myelosuppression or other significant adverse events.
Until recently, the outcomes of patients with relapsed ALL were poor, with only 7% alive at 5 years. 4 Innovative approaches, including new monoclonal antibody therapies (the anti-CD22 antibody-drug conjugate inotuzumab ozogamicin), the bispecific antibody construct blinatumomab, and CAR T-cell therapies, have recently shown promise for patients with R-R ALL. However, the observed improvements remain modest, and the cure rates are less than 20%. [5] [6] [7] [8] Our study shows that a significant and safe improvement can occur through the combination of low-intensity chemotherapy with these new agents, particularly in salvage 1. The median survival of 25 months appears superior to the survival associated with standard chemotherapy and to the The immunochemotherapy combination of inotuzumab and mini-hyper-CVD with or without blinatumomab is safe and effective in patients with acute lymphoblastic leukemia in first salvage. New strategies, including a weekly schedule of lower doses of inotuzumab, the sequential use of blinatumomab, and the selection of the least hepatotoxic transplant preparative regimens, may further improve outcomes. Cancer October 15, 2018 survival associated with the use of either blinatumomab or inotuzumab as monotherapy in salvage 1. ASCT is still considered the only curative treatment option for R-R ALL, with salvage therapies being used as a bridge to ASCT. 20, 21 This is particularly true in salvage 1. In this study, almost half of the treated patients subsequently underwent ASCT. The favorable outcomes of these patients are in line with our previous report, which showed that ASCT for patients with morphologic and flow MRD responses in salvage 1 resulted in the best outcomes, with a cure rate approaching 50%. 9 This is in contrast to the outcomes of patients treated in salvage 2, where the achievement of a flow MRD response and subsequent ASCT had no impact on survival.
The combination of low-intensity chemotherapy with inotuzumab was safe with a low rate of early mortality (4%) and did not result in increased myelosuppression, with most cycles being delivered within 3 to 5 weeks as designed. Liver toxicities and VOD are known to occur with inotuzumab treatment. In this study, these rates were 17% and 10%, respectively, and were similar to previously reported rates. 6, 16, 22 Several modifications, including the use of lower weekly doses of inotuzumab and the sequential use of blinatumomab during the consolidation phase and before ASCT (a longer time interval between the last inotuzumab dose and ASCT), were implemented to decrease this rate. We have previously reported fewer hepatic adverse events and VOD with the weekly schedule of inotuzumab 21 ; these adverse events were probably related to the peak levels of inotuzumab. The lower weekly dose schedule was associated with a lower clearance rate, a lower loading peak, and a better area under the curve and, consequently, a better safety profile. The addition of blinatumomab allowed distancing ASCT Cancer October 15, 2018 from the last dose of inotuzumab without compromising efficacy. Although the follow-up is short and these results are preliminary, this strategy appears to be successful, with a decrease in the VOD rates (0% vs 13%), but longer follow-up is needed. Further improvement of outcomes might be achieved with optimal selection of the transplant preparative regimen to minimize further hepatotoxicity and with the use of VOD-preventive measures (eg, ursodiol and defibrotide). CAR T-cell therapies are an exciting development in cancer treatment. In a recent report of 83 adults treated with CD19 CAR T-cells, the CR rate was 83% (56% among all enrolled patients), and the median event-free survival and OS were 6.1 and 12.9 months, respectively. 8 The rates of grade 3 or higher cytokine release syndrome and neurologic events were 26% and 42%, respectively. Thus, although a direct comparison cannot be made with our results (eg, salvage status, disease burden, and safety profile), a safe and effective combination of low-intensity chemotherapy and inotuzumab with or without blinatumomab compares favorably with the CAR T-cell strategy, particularly because the best outcomes with CAR T-cells were obtained in patients with minimal disease (marrow blasts < 5%), whereas our regimen was used in patients with full relapse. Therefore, the lower intensity regimen seems currently preferable during first relapse. However, these treatment modalities are not competitive but rather are complementary and could be administered sequentially to produce the deepest and most sustainable remissions possible. The rational combination of monoclonal antibodies, bispecific antibody constructs, and CAR T-cells may reduce the need for long-term intensive chemotherapy and may obviate the need for ASCT in many patients.
In summary, the combination of low-intensity chemoimmunotherapy is safe and highly effective in patients with ALL in first salvage. The new strategies, including a weekly schedule of lower doses of inotuzumab, the sequential use of blinatumomab, and the selection of the least hepatotoxic transplant preparative regimens, may further improve outcomes.
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